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OBJECTIVES This study sought to assess the risks associated with right heart catheter procedures in patients
with pulmonary hypertension.
BACKGROUND Right heart catheterization, pulmonary vasoreactivity testing, and pulmonary angiography are
established diagnostic tools in patients with pulmonary hypertension, but the risks associated
with these procedures have not been systematically evaluated in a multicenter study.
METHODS We performed a multicenter 5-year retrospective and 6-month prospective evaluation of
serious adverse events related to right heart catheter procedures in patients with pulmonary
hypertension, as defined by a mean pulmonary artery pressure 25 mm Hg at rest,
undergoing right heart catheterization with or without pulmonary vasoreactivity testing or
pulmonary angiography.
RESULTS During the retrospective period, 5,727 right heart catheter procedures were reported, and
1,491 were reported from the prospective period, for a total of 7,218 right heart catheter
procedures performed. The results from the retrospective and the prospective analyses were
almost identical. The overall number of serious adverse events was 76 (1.1%, 95% confidence
interval 0.8% to 1.3%). The most frequent complications were related to venous access (e.g.,
hematoma, pneumothorax), followed by arrhythmias and hypotensive episodes related to
vagal reactions or pulmonary vasoreactivity testing. The vast majority of these complications
were mild to moderate in intensity and resolved either spontaneously or after appropriate
intervention. Four fatal events were recorded in association with any of the catheter
procedures, resulting in an overall procedure-related mortality of 0.055% (95% confidence
interval 0.01% to 0.099%).
CONCLUSIONS When performed in experienced centers, right heart catheter procedures in patients with
pulmonary hypertension are associated with low morbidity and mortality rates. (J Am Coll
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.07.061Cardiol 2006;48:2546–52) © 2006 by the American College of Cardiology Foundation
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Dnvasive diagnostic tests, including right heart catheteriza-
ion, pulmonary vasoreactivity testing, and pulmonary an-
iography, remain essential tools in the diagnosis and
ubsequent management of patients with pulmonary hyper-
ension (1,2). Right heart catheterization is the only method
hat can definitively establish a hemodynamic diagnosis of
ulmonary hypertension because it directly measures pul-
onary artery pressure and cardiac function. For this
eason, major clinical trials in pulmonary hypertension often
equire right heart catheterization to establish a definitive
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niversity Leipzig, Leipzig, Germany; ††Internal Medicine I, University Hospital Carl
ustav Carus of Technical University Dresden, Dresden, Germany; ‡‡Division of
ardiovascular Medicine, Department of Internal Medicine, University of Michigan aiagnosis before study entry. In addition, repeat right heart
atheterizations are often used to assess hemodynamic
fficacy of novel treatments (3–10). However, the safety of
ight heart catheterization has never been formally assessed
n an extensive multicenter evaluation, which is surprising
ecause patients with severe pulmonary hypertension are
emodynamically fragile. Complications related to right
eart catheterization in patients with pulmonary hyperten-
ion were reported in the literature soon after right heart
atheterization was introduced into clinical medicine
ealth System, Ann Arbor, Michigan; §§Liu Center for Pulmonary Hypertension, Los
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December 19, 2006:2546–52 Risk of Right Heart Catheterization11,12). In 1984, Fuster et al. (13) reported 5 fatal compli-
ations associated with 120 right heart catheterizations
erformed in patients with severe pulmonary hypertension.
en serious adverse events but no deaths were noted among
87 procedures documented in the National Institutes of
ealth registry on pulmonary hypertension (14). More
ecent data on the safety of right heart catheterization in
atients with pulmonary hypertension are unavailable.
Pulmonary vasoreactivity testing with inhaled nitric oxide
NO), intravenous epoprostenol, or intravenous adenosine is
ecommended as part of the diagnostic workup of patients
ith pulmonary arterial hypertension (1,2,15) because pa-
ients who are acutely vasoreactive may benefit from high-
ose, long-term calcium channel blocker therapy (16).
gain, the safety of these procedures has not been assessed
n multicenter studies.
Pulmonary angiography is often performed when the
ossibility of chronic thromboembolic pulmonary hyperten-
ion is raised and, if present, to assess operability for
ulmonary endarterectomy (17,18). Pulmonary angiography
as been associated with fatal complications (12,19–22),
lthough some small case series document a low incidence
f serious complications, especially when nonionic contrast
gents are selectively injected into the pulmonary arteries
23,24). A series of 402 patients with pulmonary hyperten-
ion reported no procedure-related mortality (25). In con-
rast, a more recent survey of 202 pulmonary angiographies
erformed in patients with pulmonary hypertension re-
orted three procedure-related fatal complications (26).
Overall, the current state of knowledge on the safety of
ight heart catheter procedures in patients with pulmonary
ypertension is based predominantly on single-center, ret-
ospective analyses with relatively small sample sizes. There-
ore, we launched a multicenter evaluation to obtain a
eliable estimate of the risks associated with these
rocedures.
ATIENTS AND METHODS
ifteen centers with an established record of treating pa-
ients with pulmonary hypertension participated in this
tudy. The period of data collection was divided into 2 parts:
retrospective arm from January 1, 2000, through Decem-
er 31, 2004, and a prospective arm from January 1, 2005,
hrough June 30, 2005. The participating centers agreed to
ontribute data from all right heart catheter procedures that
ere performed within the indicated time frames in patients
ith pulmonary hypertension as defined by a mean pulmo-
Abbreviations and Acronyms
CI  confidence interval
NO  nitric oxide
PAH  pulmonary arterial hypertensionary artery pressure 25 mm Hg at rest (1). tFor the retrospective arm, each center reported aggregate
ata based on chart log review on the number and types of
ight heart catheter procedures performed, associated seri-
us adverse events, and patient diagnosis. The definition of
serious adverse event was in accordance with the Interna-
ional Conference on Harmonization guidelines and in-
luded any event that was causally related to the interven-
ion or occurred within 24 h after the procedure, and: 1) was
edically significant, 2) required intervention to prevent an
dverse outcome, 3) resulted in hospital admission or
rolongation of hospitalization, 4) was life-threatening, or
) resulted in disability or death. For every serious adverse
vent recorded, details of the procedure, adverse event,
ntervention undertaken, and outcome were obtained.
For the prospective arm, a standardized data form was
sed to collect information about diagnosis, hemodynamic
ariables, and details of each procedure performed, regard-
ess of whether or not a serious adverse event occurred.
The study protocol was approved by the institutional
eview boards of all participating centers, and written
nformed consent was obtained from all patients whose data
ere used for the prospective analysis.
tatistical analysis. Results are reported as mean values 
tandard deviation, with 95% confidence intervals (CI)
here appropriate.
ESULTS
able 1 depicts the number of right heart catheter proce-
ures performed and patient classification by pulmonary
ypertension type. A total number of 7,218 right heart
atheter procedures were reported from 15 centers in the
.S. and Europe. There were 5,727 procedures in the
etrospective arm and 1,491 procedures in the prospective
rm. Of the 7,218 procedures, 5,267 (73.0%) included
ulmonary vasoreactivity testing, and 1,214 (16.8%) in-
luded pulmonary angiography.
The most common underlying diseases were pulmonary
rterial hypertension (PAH) (51.5%), followed by chronic
hromboembolic pulmonary hypertension (28.1%), pulmo-
ary hypertension associated with left heart disease (9.2%),
nd pulmonary hypertension associated with lung disease
7.1%).
Table 2 shows the hemodynamic values of patients in the
rospective analysis. Table 3 provides an overview of the
otal number of vasoreactivity testing procedures performed
nd the agents used for vasoreactivity testing. Overall,
nhaled NO (44.8%) and inhaled iloprost (29.6%) were the
ost commonly used agents for acute vasoreactivity testing.
able 4 lists the venous access sites used during the
rospective period. The internal jugular vein was the pre-
erred access site (72.7% of all procedures) and was associ-
ted with a very low rate of access-related complications
0.3%). Most operators used ultrasound guiding only when
hey experienced difficulties accessing the jugular vein.
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Risk of Right Heart Catheterization December 19, 2006:2546–52The catheter procedures were performed by pulmonolo-
ists (57%) or cardiologists (43%). Pulmonary angiographies
ere performed either by radiologists or by cardiologists.
xcept for the pulmonary angiographies, the vast majority
90%) of the catheter procedures were done with balloon-
ipped catheters. Whether the catheter studies were per-
ormed in an outpatient or an inpatient setting depended
ostly on local arrangements and varied substantially be-
ween U.S. centers and European centers. Overall, more
han 90% of the catheterization procedures performed in the
.S. were done in the outpatient setting, whereas more than
0% of the procedures performed in Europe were done in
he inpatient setting. There was no difference in the rate of
erious adverse events between U.S. centers and European
enters.
rocedure-related mortality. In the retrospective analysis,
here were 3 fatal events related to any of the 5,727 catheter
rocedures (0.052%, 95% CI 0% to 0.111%). A single fatal
vent was reported among the 1,491 procedures in the
rospective analysis (0.067%, 95% CI 0% to 0.197%),
Table 1. Number of Procedures and Baseline C
Retrospectiv
2000–
Total number of procedures 5,727 (
Vasoreactivity testing 4,043 (
Pulmonary angiographies 1,050 (
Total number of patients* 4,990 (
PAH 2,499 (
Idiopathic PAH 1,540 (
Familial PAH 0
PAH, connective tissue disease 371 (
PAH, congenital heart disease 312 (
PAH, portal hypertension 182 (
PAH, HIV 94 (
PAH, appetite suppressants 0 (
PH, left heart disease 480 (
PH, lung disease 323 (
PH, COPD 133 (
PH, interstitial lung disease 190 (
CTEPH 1,493 (
Miscellaneous† 195 (
Values expressed as n (%). *The number of patients is no
underwent repeated right heart catheterization. †Miscellane
matosis, pulmonary hypertension related to the usage of amp
obstructive sleep apnea, sickle cell disease, thalasemia, fibros
COPD  chronic obstructive pulmonary disease; CTEP
human immunodeficiency virus; PAH  pulmonary arterial
able 2. Baseline Hemodynamics of Patients Undergoing Right
eart Catheterization in 2005
Prospective Analysis
January–June 2005
umber of procedures 1,491
ean right atrial pressure (mm Hg) 8  6 (2–48)
APmean (mm Hg) 47  15 (26–153)
ardiac index (l/min/m2) 2.7  1.9 (0.7–10.4)
VR (dynes·s·cm5) 749  510 (32–8,560)
vO2 (%) 62  9 (27–91)
alues expressed as n or mean  SD (range).i
PAPmean  mean pulmonary arterial pressure; PVR  pulmonary vascular
esistance; SvO2  mixed venous oxygen saturation.esulting in an overall number of 4 fatal events among 7,218
rocedures (0.055%, 95% CI 0.01% to 0.099%). All of these
vents occurred in patients who underwent either elective
npatient (n  3) or outpatient (n  1) catheter studies and
ho were hemodynamically stable before the procedures.
Of the 4 fatal events, only 2 were directly related to right
eart catheterization: a 67-year-old woman with PAH
ssociated with connective tissue disease died of massive
emoptysis and asphyxiation after rupture of the pulmonary
rtery during an elective procedure with a balloon-tipped
atheter. Another patient with presumed chronic thrombo-
mbolic pulmonary hypertension had an arrest 15 min after
ulmonary angiography. An autopsy showed diffuse in-
rapulmonary hemorrhage, plexogenic pulmonary arteriopa-
hy, intact major pulmonary arteries, and right heart failure.
he pathogenesis of this catastrophic event remained un-
xplained. The other 2 fatal events did not seem to be
irectly related to any right heart catheter procedure. One
atient with idiopathic PAH died suddenly while being
repared for catheterization. An autopsy showed a massive
ulmonary embolism. Warfarin treatment had been discon-
inued 5 days before the event without the use of heparin.
he physicians in charge linked this event directly to
iscontinuation of warfarin. The last patient was found dead
n his room the morning after an apparently uneventful right
eart catheterization for pulmonary hypertension associated
ith dilated cardiomyopathy. An autopsy was denied. The
aregivers thought that the death was related to his under-
ying diagnosis and not causally related to the procedure.
erious adverse events. A total of 57 serious adverse
vents, including the 3 fatalities mentioned above, occurred
cteristics of Patients
alysis Prospective Analysis
January–June 2005
Total
2000–2005
1,491 (100) 7,218 (100)
1,224 (82.1) 5,267 (73.0)
164 (11.0) 1,214 (16.8)
1,491 (100) 6,481 (100)
837 (56.1) 3,336 (51.5)
444 (29.8) 1,984 (30.6)
25 (1.7) 25 (0.4)
145 (9.7) 516 (8.0)
65 (4.4) 377 (5.8)
81 (5.4) 263 (4.1)
51 (3.4) 145 (2.2)
26 (1.7) 26 (0.4)
114 (7.6) 594 (9.2)
137 (9.2) 460 (7.1)
48 (3.2) 181 (2.8)
89 (6.0) 279 (4.3)
327 (21.9) 1,820 (28.1)
76 (5.1) 271 (4.2)
ical to the number of procedures because several patients
ludes pulmonary vasculitis, pulmonary capillary hemangio-
ine or metamphetamine, obesity hypoventilation syndrome,
diastinitis, and pulmonary vascular stenoses.
chronic thromboembolic pulmonary hypertension; HIV 
tension; PH  pulmonary hypertension.hara
e An
2004
100)
70.6)
18.3)
100)
50.0)
30.9)
7.4)
6.3)
3.7)
1.9)
0)
9.6)
6.5)
2.7)
3.8)
29.9)
3.9)
t ident
ous inc
hetam
ing men association with the 5,727 retrospectively analyzed pro-
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December 19, 2006:2546–52 Risk of Right Heart Catheterizationedures (1.0%, 95% CI 0.7% to 1.3%). Nineteen serious
dverse events including 1 fatality were reported among the
,491 prospectively analyzed procedures (1.3%, 95% CI
.7% to 1.9%). Thus, the total number of serious adverse
vents was 76 among 7,218 procedures (1.1%, 95% CI 0.9%
o 1.3%).
Tables 5 and 6 provide the classification of serious adverse
vents encountered, the procedures to which they were
elated, and detailed descriptions of all nonfatal serious
dverse events. With the exception of the 4 fatalities, most
f the remaining 72 serious adverse events were mild to
oderate in severity and resolved quickly, either without
pecific measures or with appropriate medical intervention.
nly a single patient had permanent disability resulting
rom persistent radiating pain in his leg after developing a
roin hematoma. Twenty-one nonfatal serious adverse
vents (28%) resulted in hospital admission or prolongation
f hospital stay. The majority of the nonfatal serious adverse
vents were related to obtaining venous access (n  29;
8%), right heart catheterization itself (n  22; 29%), or
ulmonary vasoreactivity testing (n  15; 20%). The most
requent complications were hematoma at puncture sites,
neumothoraces, arrhythmias, vasovagal episodes, and hy-
otensive episodes. Only 6 nonfatal serious adverse events
ere considered to be related to pulmonary angiography.
ISCUSSION
n the present retrospective and prospective surveys of compli-
ations associated with right heart catheterization, vasoreactiv-
Table 3. Agents Used for Pulmonary Vasoreac
Retrospective An
2000–2004
Number of procedures* 4,043 (100)
Inhaled nitric oxide 1,729 (42.8)
Inhaled iloprost† 1,240 (30.7)
Intravenous epoprostenol 97 (2.4)
Intravenous iloprost 49 (1.2)
Intravenous adenosine 0 (0)
Calcium channel blockers 79 (2.0)
Sildenafil 0 (0)
Others‡ 764 (18.9)
Values expressed as n (%). *Some patients were exposed to
pulmonary vasoreactivity testing was used predominantly in
treprostinil.
able 4. Venous Access Sites
Prospective
Analysis
January–June 2005
Serious Adverse
Events Related to
Venous Access
January–June 2005
umber of procedures 1,491 (100) 7 (0.5)
nternal jugular vein 1,084 (72.7) 3 (0.3)
ubclavian vein 5 (0.3) 0 (0)
emoral vein 184 (12.3) 2 (1.1)
rachial vein 203 (13.6) 2 (1.0)
nknown 15 (1) 0 (0)calues expressed as n (%).ty testing, and pulmonary angiography in patients with pul-
onary hypertension, the overall rate of serious adverse events
as 1.1% and the number of fatal complications was 0.1%.
hese numbers were lower than expected because patients with
ulmonary hypertension are a high-risk population, and fatal
omplications of invasive procedures have been repeatedly
eported in these patients (11–13,21,26,27). Earlier series from
he 1980s and 1990s reported much higher complication rates.
n the 1984 article by Fuster et al (13), catheterization-related
ortality was 4.2%. In the series of the National Institutes of
ealth registry obtained between 1981 and 1985, no fatal
vents were reported from 187 procedures, but the rate of
ajor procedure-related complications was 5.3% (14). It seems
hat a learning curve in pulmonary hypertension centers has
ontributed to reducing the risks of catheter-related complica-
ions. In fact, the complication rates from the present survey
re very similar to current procedure-related serious adverse
vent and mortality rates (1.7% and 0.11%, respectively) of left
eart catheterization and coronary angiography (28).
The serious adverse events observed in this study can be
ategorized into 4 groups according to their association with
enous access, right heart catheterization, pulmonary vaso-
eactivity testing, or pulmonary angiography. As antici-
ated, hematoma, vagal reactions, and pneumothoraces
ere the most frequent complications associated with ve-
ous access. These complications, taken together, occurred
n 1% of all procedures, a number that is consistent with
recent report of the use of pulmonary artery catheters in
he intensive care unit (29).
Overall, complications directly related to right heart
atheterization such as arrhythmias or hypotensive episodes
ere uncommon, occurring in 22 of 7,218 right heart
atheterization procedures. Although the vast majority of
hese adverse events resolved with minimal or no interven-
ion, the potential for serious complications exists. Certain
dverse events may require aggressive intervention to stabi-
ize the patient.
Pulmonary vasoreactivity testing was occasionally com-
licated by serious systemic hypotension. This occurred not
nly with the use of nonselective vasodilators such as
Testing
Prospective Analysis
January–June 2005
Total
2000–2005
1,224 (100) 5,267 (100)
628 (51.3) 2,357 (44.8)
236 (19.3) 1,476 (28)
2 (0.2) 99 (1.9)
1 (0.1) 50 (1.0)
0 (0) 0 (0)
0 (0) 79 (1.5)
270 (22.1) 270 (5.1)
87 (7.1) 851 (16.2)
than 1 agent during the procedure. †Inhaled iloprost for
an centers. ‡Others include nitrates, oxygen, and inhaledtivity
alysis
morealcium channel blockers and nitrates, but also in association
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Risk of Right Heart Catheterization December 19, 2006:2546–52ith agents that are usually considered pulmonary selective,
uch as inhaled iloprost (30). Iloprost-induced systemic
ypotension is dose related and the acute combination with
ther vasodilators such as phosphodiesterase-5 inhibitors
ncreases the risk of systemic side effects during vasoreac-
ivity testing. Inhaled iloprost is used for pulmonary vaso-
Table 5. Serious Adverse Events Related to Ri
Pulmonary Hypertension
Retrospective
2000–2
Number of procedures 5,727
Total number of serious
adverse events
57 (1
[0.7–1
Hospitalization required* 16 (0.
[0.2–0
Disabilities 1 (0.0
[0–0.0
Fatalities 3 (0.05
[0–0.11
Values expressed as n (%) [95% confidence interval]. *Includ
able 6. Description of Nonfatal Serious Adverse Events Related
ypertension Performed in the Years 2000 to 2005
Description of SAE n
otal number of nonfatal SAEs 72
elated to venous access 29
Hematoma at puncture site 10 Transfusion and surger
Vagal reaction with bradycardia
and hypotension
8 All successfully manage
Pneumothorax 5 No intervention require
Arteriovenous fistula 3 1 case resolved spontan
Puncture of carotid artery 2 No sequela with manu
Hypertensive crisis during
puncture
1 Resolved with treatmen
elated to right heart catheterization 22
Supraventricular tachycardia 7 1 resolved spontaneous
required overdrive pa
Vagal reaction with bradycardia
and hypotension
3 All successfully manage
Ventricular tachycardia 3 2 resolved after cathete
Systemic hypotension 2 1 required fluids, the o
Transient ischemic attack 2 Both resolved complete
other patient
Hypertensive crisis 2 1 with pulmonary edem
Chest pain and hemoptysis after
balloon inflation
1 Resolved without inter
Hypotension after balloon rupture 1 Resolved without inter
New right bundle branch block 1 Asymptomatic
elated to vasoreactivity testing 15
Systemic hypotension 11 Linked to intravenous
(n  2), sildenafil (n
transient catecholam
Bronchospasm during prostanoid
inhalation
4 Linked to inhaled ilopr
n  3)
elated to pulmonary angiography 6
Hypertensive crisis and pulmonary
edema after dye injection
3 Resolved with treatmen
Second-degree AV block after dye
injection
1 Required temporary pa
Chest pain after dye injection 1 Resolved spontaneously
Vomiting after dye injection 1 Resolved with corticostV  atrioventricular; PFO  patent foramen ovale; SAE  serious adverse event.eactivity testing mainly in Germany (31), which explains
hy it was used in approximately 30% of this multinational
urvey, where German centers are overrepresented. The
nternational guidelines (1,2,15) do not advise using inhaled
loprost to test for acute pulmonary vasoreactivity because of
he absence of published data on its utility as a predictor of
eart Catheter Procedures in Patients With
lysis Prospective Analysis
January–June 2005
Total
2000–2005
1,491 7,218
19 (1.3) 76 (1.1)
[0.7–1.9] [0.9–1.3]
5 (0.3) 21 (0.3)
[0–0.6] [0.2–0.4]
0 1 (0.01)
[0–0] [0–0.03]
1 (0.067) 4 (0.055)
[0–0.197] [0.01–0.099]
or prolonged hospitalization.
ight Heart Catheter Procedures in Patients With Pulmonary
Interventions and Outcomes
ired in 2 cases, persistent groin pain in 1 patient
h fluids and/or atropine
3 cases, 2 patients received chest tubes for 3 and 5 days, respectively
y, 1 patient required percutaneous intervention, and 1 required surgery
pression
equired vagal maneuvers, 1 resolved after adenosine and diltiazem, 2
and 2 required electrical cardioversion
h fluids and/or atropine
oval and 1 required antitachycardic pacing
equired fluids and catecholamines
thout specific intervention; PFO in 1 patient ascertained, unclear in the
th resolved with appropriate treatment
n
n
ostenol (n  1), inhaled iloprost (n  4), inhaled iloprost plus sildenafil
), nitrates (n  2), calcium channel blockers (n  1); all recovered, but
erapy required in 6 patients
 1) or inhaled treprostinil (original formulation, no longer in use;
ll patients
eatment
prolonged hospital stay
s but prolonged hospital stayght H
Ana
004
)
.3]
3)
.4]
2)
5]
2)
1]to R
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December 19, 2006:2546–52 Risk of Right Heart Catheterizationalcium channel blocker response. In highly experienced
enters comfortable with its use, however, it has been used
n this fashion. Although the present data do not address its
tility as a predictor, they do support its safety. Similar
onsiderations apply to the use of sildenafil for vasoreactivity
esting because it is unknown whether this drug serves as a
redictor of calcium channel blocker response.
In addition to the hypotensive episodes, there were 4
pisodes of bronchospasm after pulmonary vasoreactivity
hallenge with inhaled prostanoids, mostly with the original
reprostinil formulation; this formulation is no longer being
sed. Of note, no serious adverse events were reported in
onjunction with either inhaled NO or intravenous epopros-
enol, underlining the suitability of these compounds for
cute pulmonary vasoreactivity testing (1,2). Intravenous
denosine was not used by any of the participating centers,
reventing any statement on the safety of this agent when
sed for pulmonary vasoreactivity testing.
Pulmonary angiography was associated with few complica-
ions (7 serious adverse events among 1,214 procedures, 1 of
hem fatal), mostly hypertensive episodes with pulmonary
dema, which responded well to conventional therapy. It is
nclear why fatal alveolar hemorrhage developed in 1 patient
fter the procedure. There were no episodes of a severe allergic
eaction to the contrast medium and also no contrast-
ssociated renal failure. In addition, there were no episodes of
ight heart failure after pulmonary angiography, which may
ave been because all centers used selective injections of
ow-osmolar nonionic contrast into the right and left pulmo-
ary arteries as recommended in recent guidelines (2). This
echnique avoids major hemodynamic alterations in patients
ith pulmonary hypertension (24,32–34).
Of the 4 fatal events, only 2 were considered directly
elated to a specific right heart catheter procedure. One of
hese events, rupture of the pulmonary artery, is a known
omplication of right heart catheterization that can occur
ith any type of catheter (35). The pathogenesis of the
ther event, electromechanical dissociation and diffuse in-
rapulmonary hemorrhage after pulmonary angiography in a
atient with idiopathic PAH, remains unexplained. The 2
ther fatal events were not thought to be directly related to
he procedure. In the patient found dead the morning after
right heart catheterization for pulmonary hypertension
ssociated with dilated cardiomyopathy, considered un-
ventful by the investigator, there was no apparent causal
ssociation with the procedure. The final case of a patient
ith idiopathic PAH who died of massive pulmonary
mbolism just before catheterization serves as a reminder
hat interruption of anticoagulation can result in thrombo-
mbolic complications, even in patients without previous
hromboembolic disease, and that bridging with heparin
hould be considered. An alternative strategy could be to
eep the patients on moderate-intensity oral anticoagulants
hroughout the procedure. Preliminary data suggest that
aintaining a patient at a target international normalizedatio of 1.5 to 2.0 during the procedure may be safe withegard to both thromboembolic and hemorrhagic compli-
ations (36), although further study is needed before this
oncept should be widely used.
It is important to note that right heart catheterization,
cute pulmonary vasoreactivity testing, and pulmonary an-
iography can usually be completed within 1 to 2 h, and in
any cases, in 30 min if only a right heart catheterization
or hemodynamic measurements is made. These procedures
re often performed on an outpatient basis but in the setting
f a fully equipped cardiac catheterization laboratory. This is
ery different from using a pulmonary artery catheter in the
npatient intensive care unit setting as an aid to diagnose
nd manage a variety of critical conditions. It is this latter
etting in which controversy persists with respect to the
sefulness and safety of pulmonary artery catheters
29,37,38). Additionally, these patients are at significant
isk for infectious and thromboembolic complications re-
ated to indwelling vascular catheters that usually remain in
lace for several days (39). These complications are ex-
remely rare when right heart catheterization is performed
n the pulmonary hypertension population as discussed in
his study given the short procedural time.
The main limitation of the present survey is that it
ncluded only centers with broad expertise in caring for
atients with pulmonary hypertension, which may be a main
eason for the fact that the observed rate of serious compli-
ations was much lower than expected. Thus, the present
esults may not be extendable to less experienced centers.
owever, the complication rate of any invasive procedure is
function of the experience and skill of the operator, and
he low rate of adverse events in this study was probably
elated to the fact that the procedures were done in
igh-volume centers by experienced operators, reinforcing
he recommendation to perform these procedures only in
pecialized institutions.
In summary, the present data provide reassurance that
ight heart catheterization, pulmonary vasoreactivity testing,
nd pulmonary angiography in adult patients with pulmo-
ary hypertension are associated with a low risk of serious
omplications, at least when performed in experienced
enters.
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PPENDIX
or details regarding the number of procedures performed
y each center from this study, please see the online version
f this article.
